Seminar by Larry Stanton
|
Seminar by
Larry STANTON Humacyte Inc Date: 6 June 2018 Time: 4.30pm - 6:30pm (Open to public) Location : Discovery Theatrette L4, Matrix, Biopolis 30 Biopolis Street Singapore 138671 |
Programme
16:30 – 17:30 Turning Cells into Therapies
Larry Stanton, Humacyte Inc, United States
Host: TBA
17:30 - 18:30 Networking (F&B supported by SCSS)
16:30 – 17:30 Turning Cells into Therapies
Larry Stanton, Humacyte Inc, United States
Host: TBA
17:30 - 18:30 Networking (F&B supported by SCSS)
Speaker profile
Larry STANTON
Humacyte Inc, United States
Executive Director of Cell and Molecular Biology Research
ABSTRACT
Turning Cells into Therapies
After many years laying the foundations for cell-based therapies, several regenerative medicines are now in the clinic. One of the success stories is coming from Humacyte, a start-up biotech company in North Carolina founded upon basic science from a tissue engineering lab at Duke University. I will discuss efforts at Humacyte that align expertise in cell biology, materials science, bioengineering and clinical development to bring fully-human vascular grafts to patients.
BIOSKETCH
Dr. Stanton joined Humacyte Inc in 2017 as Executive Director of Cell and Molecular Biology Research where he currently leads a tissue engineering group that is developing transplantable, human blood vessels. Previously (2002-2016), he was a Principal Scientist and served as Deputy Director at the Genome Institute of Singapore where he retains an adjunct appointment. While at GIS his research focused upon the molecular characterization of gene regulatory networks in stem cells with the aim to direct the growth, differentiation, and reprogramming of these cells into clinically-relevant tissues and models of human diseases. Most recently, the lab generated induced pluripotent stem cells (iPSC) from patients with neurodegenerative disorders. Converting these patient-specific iPSC into various neural cell types, provides the opportunity to study in vitro the molecular basis of neurodegeneration. Dr. Stanton was a founding member of the Stem Cell Society of Singapore and served as its President in 2016.
Larry STANTON
Humacyte Inc, United States
Executive Director of Cell and Molecular Biology Research
ABSTRACT
Turning Cells into Therapies
After many years laying the foundations for cell-based therapies, several regenerative medicines are now in the clinic. One of the success stories is coming from Humacyte, a start-up biotech company in North Carolina founded upon basic science from a tissue engineering lab at Duke University. I will discuss efforts at Humacyte that align expertise in cell biology, materials science, bioengineering and clinical development to bring fully-human vascular grafts to patients.
BIOSKETCH
Dr. Stanton joined Humacyte Inc in 2017 as Executive Director of Cell and Molecular Biology Research where he currently leads a tissue engineering group that is developing transplantable, human blood vessels. Previously (2002-2016), he was a Principal Scientist and served as Deputy Director at the Genome Institute of Singapore where he retains an adjunct appointment. While at GIS his research focused upon the molecular characterization of gene regulatory networks in stem cells with the aim to direct the growth, differentiation, and reprogramming of these cells into clinically-relevant tissues and models of human diseases. Most recently, the lab generated induced pluripotent stem cells (iPSC) from patients with neurodegenerative disorders. Converting these patient-specific iPSC into various neural cell types, provides the opportunity to study in vitro the molecular basis of neurodegeneration. Dr. Stanton was a founding member of the Stem Cell Society of Singapore and served as its President in 2016.